BOARD OBSERVERS

BOARD OBSERVERS

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Board Observer
Marian T. Nakada, PhD
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc. and is based in Boston. She focuses on pharmaceutical investments in East Coast companies that are in areas of strategic interest to Johnson & Johnson. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Rodin Therapeutics, PhaseBio, and Padlock Therapeutics and currently also sits on the Board of Navitor Pharmaceuticals, Artizan Therapeutics, Twentyeight-Seven Therapeutics, the New England Venture Capital Association as well as the non-profit InnerCity Weightlifting.
Board Observer
Geneviève Guertin, MSc

Geneviève Guertin joined the Fonds de solidarité in March 2012. She is currently a Portfolio Manager, Life Sciences.

Prior to her arrival at the Fonds, Ms. Guertin spent nine years as Director, Investment Monitoring, in the life sciences sector of Société générale de financement du Québec, honing her skills in this industry. Before that, she was a financial analyst at Bell Canada.

Geneviève Guertin holds a masters degree in management science from HEC Montréal and is a Chartered Financial Analyst®.

Board Observer
Petr Denitsov, MD, PhD
Petr Denisov holds the position of Chief Scientific Expert at Pharmstandard, the largest Russian pharmaceutical company. Petr has over ten years of experience in clinical trials, namely protocol-based feasibility studies in different areas of medicine spanning more than 40 countries, having served as Business Director of the Synergy CRO Ltd (2013-201), a Russian clinical contract research and as Associate Medical Director at WorldWide Clinical Trials (2006-2013), a global clinical CRO. Petr has also served on the Board Directors of Transmedics Company (medical devices for organ transplantation) and has over 15 years of experience in different areas of medicine (pulmonology; bioequivalence studies; oncology; cardiovascular diseases) and drug development. He earned his M.D. from Saint-Petersburg State Medical University n.a. I.P.Pavlov in 1996, and his Ph.D. degree in normal physiology from the Department of Visceral Systems of the Institute of Experimental Medicine (Saint-Petersburg, Russia). His Ph.D. work was devoted to physiology of blood circulation. Petr joined EnGene’s team as a Board Observer in 2017.
Board Observer
Marian T. Nakada, PhD
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc. and is based in Boston. She focuses on pharmaceutical investments in East Coast companies that are in areas of strategic interest to Johnson & Johnson. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Rodin Therapeutics, PhaseBio, and Padlock Therapeutics and currently also sits on the Board of Navitor Pharmaceuticals, Artizan Therapeutics, Twentyeight-Seven Therapeutics, the New England Venture Capital Association as well as the non-profit InnerCity Weightlifting.
Board Observer
Geneviève Guertin, MSc

Geneviève Guertin joined the Fonds de solidarité in March 2012. She is currently a Portfolio Manager, Life Sciences.

Prior to her arrival at the Fonds, Ms. Guertin spent nine years as Director, Investment Monitoring, in the life sciences sector of Société générale de financement du Québec, honing her skills in this industry. Before that, she was a financial analyst at Bell Canada.

Geneviève Guertin holds a masters degree in management science from HEC Montréal and is a Chartered Financial Analyst®.

Board Observer
Petr Denitsov, MD, PhD
Petr Denisov holds the position of Chief Scientific Expert at Pharmstandard, the largest Russian pharmaceutical company. Petr has over ten years of experience in clinical trials, namely protocol-based feasibility studies in different areas of medicine spanning more than 40 countries, having served as Business Director of the Synergy CRO Ltd (2013-201), a Russian clinical contract research and as Associate Medical Director at WorldWide Clinical Trials (2006-2013), a global clinical CRO. Petr has also served on the Board Directors of Transmedics Company (medical devices for organ transplantation) and has over 15 years of experience in different areas of medicine (pulmonology; bioequivalence studies; oncology; cardiovascular diseases) and drug development. He earned his M.D. from Saint-Petersburg State Medical University n.a. I.P.Pavlov in 1996, and his Ph.D. degree in normal physiology from the Department of Visceral Systems of the Institute of Experimental Medicine (Saint-Petersburg, Russia). His Ph.D. work was devoted to physiology of blood circulation. Petr joined EnGene’s team as a Board Observer in 2017.